Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Ribociclib + Siremadlin|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Ribociclib||Kisqali||LEE011||CDK4/6 Inhibitor 11||Kisqali (ribociclib) is a dual CDK4/6 inhibitor, which may induce cell cycle arrest and reduce proliferation in cancer cells (PMID: 24045179). Kisqali (ribociclib) is FDA-approved in combination with an aromatase inhibitor in women with hormone receptor-positive, ERBB2 (HER2)-negative breast cancer, and in combination with Faslodex (fulvestrant) in postmenopausal women with hormone receptor-positive, ERBB2 (HER2)-negative breast cancer (FDA.gov).|
|Siremadlin||HDM201|HDM-201|NVP-HDM201||MDM2 Inhibitor 20||Siremadlin (HDM201) binds to MDM2 and inhibits its interaction with p53, which prevents p53 degradation and potentially leads to restoration of p53 signaling and increased tumor cell death (PMID: 30899200, PMID: 27542305).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02343172||Phase Ib/II||Ribociclib + Siremadlin||Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma||Completed||FRA | ESP | DEU | CAN||2|
|NCT04116541||Phase II||Alectinib Cabozantinib Ribociclib + Siremadlin||A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. (MegaMOST)||Recruiting||FRA||0|